From Reaction to Prevention: Building the Future of Global Health
Panelists
Dr. Jared Baeten
SVP of Clinical Development Virology at Gilead Sciences
Jared Baeten, MD, PhD is Senior Vice President and Virology Therapeutic Area Head at Gilead Sciences. In this role, Jared provides strategic oversight for Gilead’s HIV, Viral Hepatitis, Respiratory and Emerging Virus programs. He previously served as Vice President of Clinical Development and HIV Franchise Head at the company, leading its development strategy for HIV Treatment, Prevention, and Cure.
Jared has conducted extensive research for over two decades on HIV and other infectious diseases globally, including clinical trials, large-scale epidemiologic studies, and behavioral and implementation science research. He led the Partners PrEP Study, which led to the approval of Truvada as the first medication for pre-exposure prophylaxis (PrEP) for HIV prevention in 2012 and a second trial that led to the first global approval of the dapivirine vaginal ring as a topical microbicide for HIV prevention in women. In 2022, he oversaw the team that received the approval of Sunlenca, the first HIV capsid inhibitor and first medication for HIV dosed once every six months.
Prior to joining Gilead Sciences, Jared served as Director of the University of Washington/Fred Hutch Center for AIDS Research, Co-Principal Investigator of the NIH-funded Microbicides Trials Network, and tenured Professor of Global Health, Medicine and Epidemiology at the University of Washington, where he was the Vice Dean for Strategy and Faculty Affairs at the School of Public Health. He is Affiliate Professor of Global Health and Medicine at the University of Washington, a Fellow of the Infectious Diseases Society of America and an elected member of the American Society for Clinical Investigation. He has published over 500 scientific articles on HIV and has extensive dedication to the growth of next-generation researchers around the world. His work is driven by justice, equity, and dedication to ending the HIV epidemic for everyone, everywhere.
Jared holds a medical degree and a PhD in epidemiology from the University of Washington.
Dr. Nahid Bhadelia
Founding Director of Boston University Center on Emerging Infectious Diseases; BEACON
Dr. Bhadelia is the founding director of BU Center on Emerging Infectious Diseases. She is a board-certified infectious diseases physician and an Associate Professor at the BU School of Medicine. She served as the Senior Policy Advisor for Global COVID-19 Response for the White House COVID-19 Response Team in 2022-2023, where she coordinated the interagency programs for global COVID-19 vaccine donations from the United States and was the policy lead for Project NextGen, $5B HHS program aimed at developing next generation vaccines and treatments for pandemic prone coronaviruses. She also served as the interim Testing Coordinator for the White House MPOX Response Team. She is the Founding Director and co-founder of Biothreats Emergence, Analysis and Communications Network (BEACON), an open-source outbreak surveillance program.
Dr. Nicole Lurie
Executive Director of CEPI USA, Coalition for Epidemic Preparedness Innovation
Nicole Lurie is Executive Director Preparedness and Response at CEPI, and CEPI’s US Director. She leads the team tasked with CEPI’s operational approach to outbreak response, considering CEPI’s preparedness investments in R&D and manufacturing to develop and deliver response and preparedness plans for CEPI’s priority pathogens. Prior to joining CEPI, Nicole served an 8-year term as Assistant Secretary for Preparedness and Response, a Presidentially appointed position at the US Department of Health and Human Services. During her service, Nicole led national responses to public health emergencies including the 2009 H1N1 influenza pandemic and other infectious disease outbreaks. She also chaired the Public Health Emergency Medical Countermeasures Enterprise (PHEMCE), a US Government organization responsible for the development of medical countermeasures.
Arpa Garay
Former Chief Commercial Officer at Moderna and Chief Marketing Officer for Human Health at Merck
Nicolaus (Nick) Wilson leads Product/Marketing for Ambulatory Monitoring & Diagnostics at Philips Healthcare. In the last 12 months alone, his team has launched the first ECG AI Marketplace and managed the services and product stack, using clinical AI to support more than 1 million patients a year through their cardiovascular diagnostic journey. With 20+ years in healthcare technology, Throughout his 20+ years of experience in healthcare technology – across product, sales, marketing, and strategy – Nick has led with a passion for supporting the challenges facing patients and providers in accessing efficient care.